CAJ | 학술논문

目的：探讨生长相关癌基因产物β（growth-related gene productβ，GROβ）用于结直肠癌诊断潜在的可能性。方法：收集123例结直肠癌、88例健康对照及125例非肿瘤患者外周血清，ELISA法分析GROβ的含量；免疫发光法分析CEA及CA19-9的含量。统计分析不同临床特征结直肠癌之间GROβ的差异；ROC曲线评估GROβ、CEA和CA19-9诊断结直肠癌的敏感度和特异度。结果：结直肠癌血清GROβ浓度（中位数96.15 pg/mL）明显高于健康对照组（中位数43.28 pg/mL，P<0.01）和非肿瘤患者（中位数57.30 pg/mL，P<0.01）。GROβ水平与肿瘤TNM分期（P<0.01）及浸润深度均呈正相关（P<0.05），与肿瘤分化程度、肿瘤栓塞、淋巴结转移、肿瘤病理类型及性别无关。GROβ检测结直肠癌的敏感度和特异度分别为56.1%（69/123）和95.31%（203/213）。将GROβ、CEA和CA19-9阳性样本叠加后，诊断Ⅰ期结直肠癌的敏感度为22.2%（4/18），诊断Ⅱ期结直肠癌的敏感度为66.7%（26/39）。GROβ的ROC曲线下面积（0.834）高于CEA（0.739）和CA19-9（0.676）。结论：血清GROβ浓度可能是一个有效的结直肠癌检测指标。
목적：탐토생장상관암기인산물β（growth-related gene productβ，GROβ）용우결직장암진단잠재적가능성。방법：수집123례결직장암、88례건강대조급125례비종류환자외주혈청，ELISA법분석GROβ적함량；면역발광법분석CEA급CA19-9적함량。통계분석불동림상특정결직장암지간GROβ적차이；ROC곡선평고GROβ、CEA화CA19-9진단결직장암적민감도화특이도。결과：결직장암혈청GROβ농도（중위수96.15 pg/mL）명현고우건강대조조（중위수43.28 pg/mL，P<0.01）화비종류환자（중위수57.30 pg/mL，P<0.01）。GROβ수평여종류TNM분기（P<0.01）급침윤심도균정정상관（P<0.05），여종류분화정도、종류전새、림파결전이、종류병리류형급성별무관。GROβ검측결직장암적민감도화특이도분별위56.1%（69/123）화95.31%（203/213）。장GROβ、CEA화CA19-9양성양본첩가후，진단Ⅰ기결직장암적민감도위22.2%（4/18），진단Ⅱ기결직장암적민감도위66.7%（26/39）。GROβ적ROC곡선하면적（0.834）고우CEA（0.739）화CA19-9（0.676）。결론：혈청GROβ농도가능시일개유효적결직장암검측지표。
Objective:To confirm the potential of growth-related gene productβ(GROβ) as a biomarker for colorectal cancer. Methods:Serum GROβlevels in 123 subjects with colorectal cancer, 88 healthy controls, and 125 subjects with other diseases were measured using enzyme-linked immunosorbent assay. Serum levels of carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) in all subjects were measured using immunoluminometric assay. Statistical analyses were conducted to determine the associa-tions between serum GROβlevels and clinical parameters for colorectal cancer. The receiver operating characteristic (ROC) curves of GROβ, CEA, and CA19-9 were analyzed. Results:The serum GROβlevels were higher in patients with colorectal cancer (median=96.15 pg/mL) than in the healthy controls (median=43.28 pg/mL, P<0.01) and in patients with other diseases (median=57.30 pg/mL, P<0.01). The serum GROβlevels in patients with colorectal cancer were positively correlated with the tumor-node-metastasis staging (P<0.01) and depth of infiltration (P<0.05), but not with the histological grade, tumor embolus, lymph node metastasis, gross pathologic tu-mor type, or gender of the patients. The sensitivity and specificity of the assay for serum GROβwere 56.1%(69/123) and 95.31%(203/213), respectively. The diagnostic sensitivity was 22.2%(4/18) for stage I and 66.7%(26/39) for stage II when the data of GROβwere combined with the data of CEA and CA19-9. The ROC curve constructed with the data of GROβ(0.834) was larger than that construct-ed with the data of CEA (0.739) or CA19-9 (0.676) for discriminating colorectal cancer from the matched controls. Conclusion:These preliminary results indicated that the serum GROβlevel could be a useful biomarker for colorectal cancer diagnoses.